基于Rivastigmine结构的混合物作为潜在的多位抗阿尔茨海默氏症药物候选者
Rosalba Leuci1, Stefan Simic2, Antonio Carrieri1
1Department of Pharmacy-Pharmaceutical Sciences, University of Bari Aldo Moro, via E. Orabona 4, 70126 Bari, Italy.
Bioorganic chemistry
|October 25, 2024
概括
研究人员开发了新的rivastigmine衍生物作为阿尔茨海默病 (AD) 治疗的多向酶抑制剂. 这些化合物显示出有希望的疗效和安全性,为这种神经退行性疾病提供了潜在的新疗法.
科学领域:
- 神经科学是一个神经科学.
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 呈现出复杂的病因,对有效的治疗开发构成重大挑战.
- 现有的阿尔茨海默病治疗方法往往缺乏广泛的疗效,这凸显了对新型治疗策略的需求.
- 多向药物设计提供了一种有前途的方法来解决AD的复杂分子基础.
研究的目的:
- 合成和描述新型的利瓦斯蒂格明衍生物作为阿尔茨海默病治疗的潜在多位抑制剂.
- 为了评估这些衍生物的抑制活性与广泛的酶涉及AD的发病因子.
- 评估合成化合物的药理动力学特性和细胞毒性,以潜在的治疗应用.
主要方法:
- 新型里瓦斯蒂格明衍生物的合成.
- 对乙胆酶 (AChE),丁胆酶 (BChE),脂肪酸胺基酸酶 (FAAH),单胺氧化酶A (MAO-A) 和单胺氧化酶B (MAO-B) 的酶抑制测定.
- 使用生物分析技术进行药物动力学分析,并对多个细胞系进行细胞毒性评估.
主要成果:
- 化合物5 (ROS151) 和23表现出强大的胆酶抑制,其中ROS151对ACHE的活性明显高于里瓦斯蒂格明.
- ROS151表现出潜在的金属合物特性.
- 化合物6和8在不同的酶面板上显示了多功能抑制特征.
- 测试的利瓦斯蒂格明类杂交物显示出有利的药理动力学特性和安全的细胞毒性概况.
结论:
- 新的利瓦斯蒂格明衍生物被成功合成并被描述为广谱酶抑制剂.
- 这些化合物有可能通过多向药物设计方法来治疗阿尔茨海默病.
- 有希望的疗效,药理动力学和安全性概况表明,这些混合体是进一步治疗开发的可行候选人.
相关概念视频
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
527
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
527
01:22Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
01:29Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
2.1K
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic...
2.1K
01:28Structure-Activity Relationships and Drug Design
622
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
622
01:22Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
873
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
873
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
1.7K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.7K